Loading…
Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells
Background and Objectives The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced v...
Saved in:
| Published in: | Vox sanguinis 2016-08, Vol.111 (2), p.197-205 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 205 |
| container_issue | 2 |
| container_start_page | 197 |
| container_title | Vox sanguinis |
| container_volume | 111 |
| creator | Borghese, C. Agostini, F. Durante, C. Colombatti, A. Mazzucato, M. Aldinucci, D. |
| description | Background and Objectives
The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced variability of growth factor release.
Materials and Methods
PRP‐R/SRGF is a clinical‐grade quality solution obtained from CaCl2‐activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT).
Results
PRP‐R/SRGF was more active than FBS to expand BM‐ and AT‐derived MSCs. PRP‐R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T‐cell proliferation.
Conclusions
The clinical‐grade PRP‐R/SRGF may be used in the clinical setting for the expansion of MSCs. |
| doi_str_mv | 10.1111/vox.12405 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811292372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811292372</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3875-82a758831480510432df531a03f75f381d8f4aa0b91ed39d243a007adc6513813</originalsourceid><addsrcrecordid>eNpdkU1vEzEQhi0EoqFw4A8gS1zKwY0_a-8RbUmKKLQKn-JiTXe91MW7m9q7bfJj-K84SckBX8Yz7_OORjMIvWT0mOU3vetXx4xLqh6hCZNcECoZfYwmlEpOCkr1AXqW0g2l1HCjnqIDrqnWhdAT9KcMvvMVBPIrQu3w7QjBD2u8DDC44AYSfXW9yVILOOYKpCzgo8vFJVlMPy_msze4iX2LSygDJ1AN_i4D9b4Brvquct0Qc5rwMqP9RnarJXTJ9x3uG9y65Lrqet1CwGnISI6VCyE9R08aCMm9eIiH6Ovs3ZfyjJxfzN-Xb8-JF0YrYjhoZYxg0lDFqBS8bpRgQEWjVSMMq00jAehVwVwtippLAXkrUFcnimVZHKKjXd883-3o0mBbnzYTQOf6MVlmGOMFF5pn9PV_6E0_xi5Pt6WUFlzKTL16oMar1tV2GX0LcW3_LT4D0x1w74Nb73VG7eaiNl_Ubi9qv1382H6yg-wcPg1utXdA_G1PtNDKfv80t7Of-qM5nX-wp-IvINyiVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811573244</pqid></control><display><type>article</type><title>Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Borghese, C. ; Agostini, F. ; Durante, C. ; Colombatti, A. ; Mazzucato, M. ; Aldinucci, D.</creator><creatorcontrib>Borghese, C. ; Agostini, F. ; Durante, C. ; Colombatti, A. ; Mazzucato, M. ; Aldinucci, D.</creatorcontrib><description>Background and Objectives
The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced variability of growth factor release.
Materials and Methods
PRP‐R/SRGF is a clinical‐grade quality solution obtained from CaCl2‐activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT).
Results
PRP‐R/SRGF was more active than FBS to expand BM‐ and AT‐derived MSCs. PRP‐R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T‐cell proliferation.
Conclusions
The clinical‐grade PRP‐R/SRGF may be used in the clinical setting for the expansion of MSCs.</description><identifier>ISSN: 0042-9007</identifier><identifier>EISSN: 1423-0410</identifier><identifier>DOI: 10.1111/vox.12405</identifier><identifier>PMID: 27077937</identifier><identifier>CODEN: VOSAAD</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adipose Tissue - cytology ; apheresis ; Blood Platelets - cytology ; Blood Platelets - drug effects ; Blood Platelets - metabolism ; Bone Marrow Cells - cytology ; Calcium Chloride - pharmacology ; Cell Differentiation ; Cell Proliferation ; Cells, Cultured ; cellular therapy ; cytokine ; Cytokines - analysis ; Enzyme-Linked Immunosorbent Assay ; Humans ; Intercellular Signaling Peptides and Proteins - analysis ; mesenchymal stem cells ; Mesenchymal Stromal Cells - cytology ; Mesenchymal Stromal Cells - metabolism ; Phenotype ; platelet concentrates ; Platelet-Rich Plasma - metabolism ; Regenerative Medicine</subject><ispartof>Vox sanguinis, 2016-08, Vol.111 (2), p.197-205</ispartof><rights>2016 International Society of Blood Transfusion</rights><rights>2016 International Society of Blood Transfusion.</rights><rights>Copyright © 2016 International Society of Blood Transfusion</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27077937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borghese, C.</creatorcontrib><creatorcontrib>Agostini, F.</creatorcontrib><creatorcontrib>Durante, C.</creatorcontrib><creatorcontrib>Colombatti, A.</creatorcontrib><creatorcontrib>Mazzucato, M.</creatorcontrib><creatorcontrib>Aldinucci, D.</creatorcontrib><title>Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells</title><title>Vox sanguinis</title><addtitle>Vox Sang</addtitle><description>Background and Objectives
The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced variability of growth factor release.
Materials and Methods
PRP‐R/SRGF is a clinical‐grade quality solution obtained from CaCl2‐activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT).
Results
PRP‐R/SRGF was more active than FBS to expand BM‐ and AT‐derived MSCs. PRP‐R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T‐cell proliferation.
Conclusions
The clinical‐grade PRP‐R/SRGF may be used in the clinical setting for the expansion of MSCs.</description><subject>Adipose Tissue - cytology</subject><subject>apheresis</subject><subject>Blood Platelets - cytology</subject><subject>Blood Platelets - drug effects</subject><subject>Blood Platelets - metabolism</subject><subject>Bone Marrow Cells - cytology</subject><subject>Calcium Chloride - pharmacology</subject><subject>Cell Differentiation</subject><subject>Cell Proliferation</subject><subject>Cells, Cultured</subject><subject>cellular therapy</subject><subject>cytokine</subject><subject>Cytokines - analysis</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Humans</subject><subject>Intercellular Signaling Peptides and Proteins - analysis</subject><subject>mesenchymal stem cells</subject><subject>Mesenchymal Stromal Cells - cytology</subject><subject>Mesenchymal Stromal Cells - metabolism</subject><subject>Phenotype</subject><subject>platelet concentrates</subject><subject>Platelet-Rich Plasma - metabolism</subject><subject>Regenerative Medicine</subject><issn>0042-9007</issn><issn>1423-0410</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpdkU1vEzEQhi0EoqFw4A8gS1zKwY0_a-8RbUmKKLQKn-JiTXe91MW7m9q7bfJj-K84SckBX8Yz7_OORjMIvWT0mOU3vetXx4xLqh6hCZNcECoZfYwmlEpOCkr1AXqW0g2l1HCjnqIDrqnWhdAT9KcMvvMVBPIrQu3w7QjBD2u8DDC44AYSfXW9yVILOOYKpCzgo8vFJVlMPy_msze4iX2LSygDJ1AN_i4D9b4Brvquct0Qc5rwMqP9RnarJXTJ9x3uG9y65Lrqet1CwGnISI6VCyE9R08aCMm9eIiH6Ovs3ZfyjJxfzN-Xb8-JF0YrYjhoZYxg0lDFqBS8bpRgQEWjVSMMq00jAehVwVwtippLAXkrUFcnimVZHKKjXd883-3o0mBbnzYTQOf6MVlmGOMFF5pn9PV_6E0_xi5Pt6WUFlzKTL16oMar1tV2GX0LcW3_LT4D0x1w74Nb73VG7eaiNl_Ubi9qv1382H6yg-wcPg1utXdA_G1PtNDKfv80t7Of-qM5nX-wp-IvINyiVQ</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Borghese, C.</creator><creator>Agostini, F.</creator><creator>Durante, C.</creator><creator>Colombatti, A.</creator><creator>Mazzucato, M.</creator><creator>Aldinucci, D.</creator><general>Blackwell Publishing Ltd</general><general>S. Karger AG</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201608</creationdate><title>Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells</title><author>Borghese, C. ; Agostini, F. ; Durante, C. ; Colombatti, A. ; Mazzucato, M. ; Aldinucci, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3875-82a758831480510432df531a03f75f381d8f4aa0b91ed39d243a007adc6513813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adipose Tissue - cytology</topic><topic>apheresis</topic><topic>Blood Platelets - cytology</topic><topic>Blood Platelets - drug effects</topic><topic>Blood Platelets - metabolism</topic><topic>Bone Marrow Cells - cytology</topic><topic>Calcium Chloride - pharmacology</topic><topic>Cell Differentiation</topic><topic>Cell Proliferation</topic><topic>Cells, Cultured</topic><topic>cellular therapy</topic><topic>cytokine</topic><topic>Cytokines - analysis</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Humans</topic><topic>Intercellular Signaling Peptides and Proteins - analysis</topic><topic>mesenchymal stem cells</topic><topic>Mesenchymal Stromal Cells - cytology</topic><topic>Mesenchymal Stromal Cells - metabolism</topic><topic>Phenotype</topic><topic>platelet concentrates</topic><topic>Platelet-Rich Plasma - metabolism</topic><topic>Regenerative Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borghese, C.</creatorcontrib><creatorcontrib>Agostini, F.</creatorcontrib><creatorcontrib>Durante, C.</creatorcontrib><creatorcontrib>Colombatti, A.</creatorcontrib><creatorcontrib>Mazzucato, M.</creatorcontrib><creatorcontrib>Aldinucci, D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Vox sanguinis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borghese, C.</au><au>Agostini, F.</au><au>Durante, C.</au><au>Colombatti, A.</au><au>Mazzucato, M.</au><au>Aldinucci, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells</atitle><jtitle>Vox sanguinis</jtitle><addtitle>Vox Sang</addtitle><date>2016-08</date><risdate>2016</risdate><volume>111</volume><issue>2</issue><spage>197</spage><epage>205</epage><pages>197-205</pages><issn>0042-9007</issn><eissn>1423-0410</eissn><coden>VOSAAD</coden><abstract>Background and Objectives
The aim of our study was to test a platelet‐rich plasma releasate (PRP‐R/SRGF) from CaCl2‐activated platelets as a source of growth factors for the expansion of mesenchymal stromal cells (MSCs). PRP‐R/SRGF, obtained with a low‐cost procedure, is characterized by a reduced variability of growth factor release.
Materials and Methods
PRP‐R/SRGF is a clinical‐grade quality solution obtained from CaCl2‐activated platelets. Its activity was evaluated by measuring the proliferation, the phenotype, the differentiation potential and the immunosuppressive properties of MSCs derived from bone marrow (BM) and adipose tissue (AT).
Results
PRP‐R/SRGF was more active than FBS to expand BM‐ and AT‐derived MSCs. PRP‐R/SRGF treatment did not affect the expression of typical MSCs surface markers, neither MSCs differentiation potential nor their capability to inhibit activated T‐cell proliferation.
Conclusions
The clinical‐grade PRP‐R/SRGF may be used in the clinical setting for the expansion of MSCs.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27077937</pmid><doi>10.1111/vox.12405</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9007 |
| ispartof | Vox sanguinis, 2016-08, Vol.111 (2), p.197-205 |
| issn | 0042-9007 1423-0410 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811292372 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adipose Tissue - cytology apheresis Blood Platelets - cytology Blood Platelets - drug effects Blood Platelets - metabolism Bone Marrow Cells - cytology Calcium Chloride - pharmacology Cell Differentiation Cell Proliferation Cells, Cultured cellular therapy cytokine Cytokines - analysis Enzyme-Linked Immunosorbent Assay Humans Intercellular Signaling Peptides and Proteins - analysis mesenchymal stem cells Mesenchymal Stromal Cells - cytology Mesenchymal Stromal Cells - metabolism Phenotype platelet concentrates Platelet-Rich Plasma - metabolism Regenerative Medicine |
| title | Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2-activated platelet concentrates promoted expansion of mesenchymal stromal cells |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A14%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical-grade%20quality%20platelet-rich%20plasma%20releasate%20(PRP-R/SRGF)%20from%20CaCl2-activated%20platelet%20concentrates%20promoted%20expansion%20of%20mesenchymal%20stromal%20cells&rft.jtitle=Vox%20sanguinis&rft.au=Borghese,%20C.&rft.date=2016-08&rft.volume=111&rft.issue=2&rft.spage=197&rft.epage=205&rft.pages=197-205&rft.issn=0042-9007&rft.eissn=1423-0410&rft.coden=VOSAAD&rft_id=info:doi/10.1111/vox.12405&rft_dat=%3Cproquest_pubme%3E1811292372%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i3875-82a758831480510432df531a03f75f381d8f4aa0b91ed39d243a007adc6513813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1811573244&rft_id=info:pmid/27077937&rfr_iscdi=true |